# Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

> **NCT03614728** · PHASE1,PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 30 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK3326595
- **DRUG:** 5-Azacitidine

## Key facts

- **NCT ID:** NCT03614728
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-16
- **Primary completion:** 2022-01-11
- **Final completion:** 2022-01-11
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Trial terminated due to internal review of clinical data in context of indication under investigation
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03614728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03614728, "Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03614728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*